Intra-Cellular Therapies edges closer to FDA win for Caplyta in depression

Intra-Cellular Therapies has secured another win with positive topline results from a Phase III study evaluating Caplyta (lumateperone) as an adjunctive therapy in patients with major depressive disorder (MDD).